9 Meters Biopharma, Inc. (NMTR) News

9 Meters Biopharma, Inc. (NMTR): $0.07

0.05 (-42.97%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add NMTR to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#200 of 379

in industry

Filter NMTR News Items

NMTR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NMTR News From Around the Web

Below are the latest news stories about 9 METERS BIOPHARMA INC that investors may wish to consider to help them evaluate NMTR as an investment opportunity.

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.

Yahoo | May 30, 2023

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.

Yahoo | May 15, 2023

9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity.

Yahoo | April 5, 2023

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2022.

Yahoo | March 28, 2023

9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock

Yahoo | March 15, 2023

9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common

Yahoo | March 14, 2023

9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference.

Yahoo | March 7, 2023

9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled to present on Monday, February 6, 2023, at 10:00 AM ET as part of the BIO CEO & Investor Conference being held in New York City.

Yahoo | January 31, 2023

9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome (SBS). The study design follows the Company's successful End-of-Phase 2 meeting and incorporates input received from the U.S.

Yahoo | November 29, 2022

9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced a continuing collaboration agreement with Gustave Roussy, a world-renowned cancer center in France, using 9 Meters' small molecule tight junction microbiome modulator NM-102. NM-102 is presumed to prevent gut microbial metabolites and antigens from trafficking into the systemic circulation.

Yahoo | November 14, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!